Head to Head Review: Medifast (NYSE:MED) and Prenetics Global (NASDAQ:PRE)

Medifast (NYSE:MED) and Prenetics Global (NASDAQ:PRE) are both small-cap consumer staples companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability and risk.

Profitability

This table compares Medifast and Prenetics Global’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medifast	-8.08%	-6.69%	-5.25%
Prenetics Global	-62.45%	-20.33%	-15.42%

Insider and Institutional Ownership

95.5% of Medifast shares are owned by institutional investors. Comparatively, 25.0% of Prenetics Global shares are owned by institutional investors. 3.7% of Medifast shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Medifast and Prenetics Global”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medifast	$316.93 million	0.40	-$18.67 million	($2.33)	-4.85
Prenetics Global	$92.39 million	3.54	-$37.71 million	($4.58)	-4.24

Medifast has higher revenue and earnings than Prenetics Global. Medifast is trading at a lower price-to-earnings ratio than Prenetics Global, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Medifast and Prenetics Global, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medifast	1	2	0	0	1.67
Prenetics Global	1	0	4	0	2.60

Medifast currently has a consensus price target of $12.00, indicating a potential upside of 6.19%. Prenetics Global has a consensus price target of $34.25, indicating a potential upside of 76.55%. Given Prenetics Global’s stronger consensus rating and higher possible upside, analysts plainly believe Prenetics Global is more favorable than Medifast.

Volatility and Risk

Medifast has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, Prenetics Global has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500.

Summary

Medifast beats Prenetics Global on 9 of the 14 factors compared between the two stocks.

About Medifast

Medifast, Inc., through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.